Recently published clinical trial data suggests AB-Biotics’ probiotics strains for infant formula can play a role in reducing colic and functional constipation severity in infants with functional gastrointestinal disorders (FGIDs).
FGIDs are brain-gut interaction disorders, comprising regurgitation, infant colic and functional constipation. At present, the company says, there are few effective ways to improve of FGIDs in infants, with limited and conflicting evidence demonstrating the mechanisms, safety and health benefits of probiotics in this field. The study, which involved a total of 36 infants, was designed to investigate the potential of the company’s blend of two probiotic strains Bifidobacterium longum KABP042 and Pediococcus pentosaceus KABP041, in pediatric FGID.
The researchers concluded a daily dose of AB-Biotics’ probiotic strains for 14 days was safe and effective at reducing the severity of FGIDs, helping to decrease colic and constipation symptoms. Moreover, the efficacy of the strains was confirmed independent of feeding type (breastfed or formula), mode of birth delivery or use of other medications, the company says.
Sergi Audivert Brugue, Executive Director, AB-Biotics said: “Growing evidence demonstrates the important role of probiotics during the first 1,000 days – that is from the moment a child is conceived until they have reached two years of age (24 months).
”The benefits of probiotics in gut health, especially, is gaining rising interest in the infant nutrition space, including their potential role in FGIDs, a condition which causes significant discomfort in infants and distress for parents. The new clinical evidence published in the Frontier journal is an exciting step forward for innovation in the field, which we hope can be translated into novel probiotic solutions targeted towards gut health-related issues, such as FGID, one day.”
